The $1.75M contract represents ~22% of BMRA's market cap, making this a material revenue catalyst for a micro-cap. Monitor for subsequent SOW execution and milestone announcements, which would confirm revenue recognition. The CDMO strategy diversifies revenue without diluting focus on inFoods IBS.
Price Chart
Executive Summary
Biomerica entered a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assays, with an initial target fee of over $1.75 million. The deal monetizes existing ELISA capabilities built for its inFoods IBS platform, providing near-term revenue visibility with minimal incremental costs. For a micro-cap with an $8M market cap, a $1.75M contract is material and validates the CDMO strategy.
Key Financial Metrics
Key Facts
- Master Services Agreement with confidential life sciences company for proprietary IVD assay development
- Initial contract development target fee of over $1.75 million across multiple Statements of Work
- Three-year initial term with automatic one-year renewals
- Work performed at FDA-licensed, ISO 13485-certified Irvine facility
- Revenue recognized on milestone-completion basis
- Capital-light structure using existing team and equipment, minimal incremental costs expected
- inFoods IBS remains primary commercial priority; CDMO is parallel revenue stream
Financial Impact
Over $1.75 million in initial development fees; material relative to $8M market cap (~22% of market cap)
Risk Factors
- Contract partner is confidential; no visibility into creditworthiness or long-term commitment
- Revenue recognition is milestone-based and contingent on SOW execution and deliverable acceptance
- Forward-looking statements subject to SOW non-execution, program cancellation, or MSA termination
- Micro-cap liquidity risk; $8M market cap means low trading volume and high volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302824 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | DEF 14A | $1.76 | awaiting T+20 | — | $1.68 (−4.55%) |
Oct 15, 2026 11d ago | 8-K | $1.85 | awaiting T+20 | — | $1.68 (−9.19%) |
Oct 8, 2026 18d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.68 (−11.11%) |
Oct 8, 2026 18d ago | EFFECT | $1.89 | awaiting T+20 | — | $1.68 (−11.11%) |
Sep 25, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.68 (+27.59%) |
Sep 24, 2026 4w ago | S-3 | $2.32 $1.68 | ▲ +27.59% | ▲ +26.11% | $1.68 (+27.59%) |
Sep 1, 2026 7w ago | Press Release | $2.09 $2.26 | ▲ +8.13% | ▲ +7.82% | $1.68 (−19.62%) |
Aug 27, 2026 8w ago | Insider Cluster | $2.14 $2.39 | ▲ +11.68% | ▲ +12.16% | $1.68 (−21.50%) |
Aug 26, 2026 8w ago | 8-K | $2.10 $2.40 | ▼ −14.29% | ▼ −14.39% | $1.68 (+20.00%) |
Jun 4, 2026 20w ago | 8-K | $2.12 $1.73 | ▼ −18.40% | ▼ −20.26% | $1.68 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers